Table 1.
Characteristics of the studies included in the meta-analysis
| ID | First Author | Year | Country | Median age | Type (Retro/Pro) | Cancer | Control | Standard | Specimen | Method | TNM stage (I-II/III-IV) | microRNAs | TN | TP | FN | FP | Cut-off | Level |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Todeschini | 2017 | Italy | 61 | Pro | 168 | 65 | Yes | serum | qPCR | 0/168 | miR-1246 | 50 | 146 | 15 | 22 | 0.41 | high |
| miR-595 | 55 | 79 | 10 | 89 | −0.29 | high | ||||||||||||
| miR-2278 | 43 | 136 | 22 | 32 | 0.26 | high | ||||||||||||
| 3 miRNAs | 50 | 141 | 15 | 27 | 0.41 | high | ||||||||||||
| 2 | Zuberi(a) | 2016 | India | NA | Pro | 70 | 70 | Yes | serum | qPCR | 33/37 | miR-125b | 54 | 44 | 16 | 26 | 3.76 | high |
| 3 | Zuberi(b) | 2016 | India | NA | Pro | 70 | 70 | Yes | serum | qPCR | 33/37 | miR-199a | 67 | 48 | 3 | 22 | 4.71 | high |
| 4 | Meng(a) | 2016 | Germany | 60 | Pro | 163 | 20 | Yes | serum | qPCR | 27/118 | miR-200a | 18 | 137 | 2 | 26 | NA | high |
| miR-200b | 20 | 86 | 0 | 77 | NA | high | ||||||||||||
| miR-200c | 20 | 51 | 0 | 112 | NA | high | ||||||||||||
| 3 miRNAs | 18 | 144 | 2 | 19 | NA | |||||||||||||
| 5 | Meng(b) | 2016 | Germany | 56 | Pro | 60 | 32 | Yes | serum | qPCR | 8/41 | miR-200a | 29 | 40 | 3 | 20 | NA | high |
| miR-200b | 29 | 56 | 3 | 4 | NA | high | ||||||||||||
| miR-200c | 27 | 51 | 5 | 9 | NA | high | ||||||||||||
| 3 miRNAs | 32 | 50 | 0 | 10 | NA | |||||||||||||
| 6 | Meng(c) | 2015 | Germany | 62 | Pro | 180 | 66 | Yes | serum | qPCR | 32/147 | miR-7 | 49 | 96 | 17 | 84 | NA | high |
| miR-25 | 42 | 166 | 24 | 14 | NA | low | ||||||||||||
| miR-93 | 41 | 158 | 25 | 22 | NA | low | ||||||||||||
| miR-429 | 63 | 107 | 3 | 73 | NA | high | ||||||||||||
| 72 | 66 | NA | 4 miRNAs | 61 | 67 | 5 | 5 | NA | ||||||||||
| 7 | Gao | 2015 | China | NA | Retro | 93 | 50 | Yes | serum | qPCR | 54/20 | miR-200c | 35 | 67 | 15 | 26 | NA | high |
| miR-141 | 36 | 64 | 14 | 29 | NA | high | ||||||||||||
| 8 | Zheng | 2013 | China | 53.75 | Retro | 134 | 70 | Yes | plasma | qPCR | 45/89 | miR-205 | 66 | 40 | 4 | 94 | NA | high |
| 9 | Suryawanshi | 2013 | USA | 65.52 | Retro | 21 | 20 | Yes | plasma | qRT-PCR | 3/18 | miR-16, 191, and 4284 | 11 | 19 | 9 | 2 | NA | high |
| 10 | Hong | 2013 | China | 58.6 | Retro | 96 | 35 | Yes | serum | qRT-PCR | 32/64 | miR-221 | 5 | 85 | 30 | 11 | NA | high |
| 11 | Guo | 2013 | China | 54.5 | Retro | 50 | 50 | Yes | serum | qRT-PCR | 35/15 | miR-92 | 38 | 40 | 12 | 10 | NA | high |
| 12 | Chung | 2013 | Korea | 57.5 | Retro | 18 | 12 | Yes | serum | qPCR | 3/14 | miR-132 | 11 | 12 | 1 | 6 | 0.0001 | low |
| miR-26a | 9 | 18 | 0 | 3 | 0.0041 | low | ||||||||||||
| let-7b | 12 | 15 | 3 | 0 | 0.066 | low | ||||||||||||
| miR-145 | 12 | 9 | 9 | 0 | 0.0011 | low | ||||||||||||
| 13 | Kan | 2012 | Australia | 63 | Retro | 28 | 28 | Yes | serum | qPCR | 1/27 | miR-200a | 10 | 24 | 18 | 4 | NA | high |
| miR-200b | 10 | 24 | 18 | 4 | NA | high | ||||||||||||
| miR-200c | 16 | 20 | 12 | 8 | NA | high | ||||||||||||
| miR-200b + 200c | 13 | 22 | 15 | 6 | NA | high |
Retro retrospective study, Pro prospective study, qPCR quantitative real-time PCR, qRT-PCR quantitative reverse transcription–PCR, TN true negatives, TP true positives, FN false negatives, FP false positives; level refers to the high or low levels of miRNA expression in blood compared with normal tissues.